KemPharm Inc., a specialty pharmaceutical company with operations in Coralville, reported a second-quarter net loss of $9.3 million, or 33 cents per basic and diluted share, compared with a net loss of $10 million, or 65 cents per basic share and 91 cents per diluted share for the same period in 2018. “Our highest priority at KemPharm has been securing a licensing agreement that maximizes the value of KP415 and KP484,” said Travis Mickle, president and CEO. “This licensing process has taken longer than expected as we have had several late entrants. Yet, we believe we are in the final phase of this process and remain optimistic about reaching a successful conclusion as soon as possible.” During the quarter, KemPharm took a number of steps to reduce its operating, general and administrative expenses, including an approximately 30% reduction in workforce compared with the end of first quarter 2019.